169 related articles for article (PubMed ID: 37989845)
21. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Robertson M; Castle PE;
Int J Cancer; 2014 Aug; 135(3):624-34. PubMed ID: 24226935
[TBL] [Abstract][Full Text] [Related]
22. Human papilloma virus genotype distribution in women with premalignant or malignant lesions of the uterine cervix.
Stuebs FA; Gass P; Dietl AK; Schulmeyer CE; Adler W; Geppert C; Hartmann A; Knöll A; Beckmann MW; Koch MC
Arch Gynecol Obstet; 2021 Sep; 304(3):751-758. PubMed ID: 33538863
[TBL] [Abstract][Full Text] [Related]
23. HIGH-RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping?
Kares S; Veijalainen O; Kholová I; Tirkkonen M; Vuento R; Huhtala H; Tuimala V; Mäenpää J; Kujala P
APMIS; 2019 Nov; 127(11):710-716. PubMed ID: 31403733
[TBL] [Abstract][Full Text] [Related]
24. High-risk human papillomavirus detection in self-collected vaginal samples compared with healthcare worker collected cervical samples among women attending gynecology clinics at a tertiary hospital in Pretoria, South Africa.
Tiiti TA; Mashishi TL; Nkwinika VV; Benoy I; Selabe SG; Bogers J; Lebelo RL
Virol J; 2021 Sep; 18(1):192. PubMed ID: 34556128
[TBL] [Abstract][Full Text] [Related]
25. Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus.
Yu S; Kwon MJ; Lee EH; Park H; Woo HY
J Med Virol; 2015 Sep; 87(9):1587-93. PubMed ID: 25914215
[TBL] [Abstract][Full Text] [Related]
26. Assessment of clinical performance of an ultrasensitive nanowire assay for detecting human papillomavirus DNA in urine.
Lee H; Choi M; Jo M; Park EY; Hwang SH; Cho Y
Gynecol Oncol; 2020 Mar; 156(3):641-646. PubMed ID: 31926639
[TBL] [Abstract][Full Text] [Related]
27. Detection assay for HPV16 and HPV18 by loop‑mediated isothermal amplification with lateral flow dipstick tests.
Kumvongpin R; Jearanaikoon P; Wilailuckana C; Sae-Ung N; Prasongdee P; Daduang S; Wongsena M; Boonsiri P; Kiatpathomchai W; Swangvaree SS; Sandee A; Daduang J
Mol Med Rep; 2017 May; 15(5):3203-3209. PubMed ID: 28339040
[TBL] [Abstract][Full Text] [Related]
28. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
[TBL] [Abstract][Full Text] [Related]
29. Internally controlled recombinase-aided amplification (IC-RAA) assays for the detection of human papillomavirus genotypes 16 and 18 using extracted DNA and samples treated with nucleic acid releasing agent.
Wang J; Liu J; Song G; Cao Z; Pan J; Li X; Gao Y; Qi J; Chen Z; Fan G; Bai X; Zhang R; Wang R; Duan Q; Li L; Shen X; Ma X
Arch Virol; 2020 Oct; 165(10):2241-2247. PubMed ID: 32681408
[TBL] [Abstract][Full Text] [Related]
30. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China.
Wang R; Guo XL; Wisman GB; Schuuring E; Wang WF; Zeng ZY; Zhu H; Wu SW
BMC Infect Dis; 2015 Jul; 15():257. PubMed ID: 26142044
[TBL] [Abstract][Full Text] [Related]
31. Redesign of a rapid, low-cost HPV typing assay to support risk-based cervical screening and management.
Desai KT; Adepiti CA; Schiffman M; Egemen D; Gage JC; Wentzensen N; de Sanjose S; Burk RD; Ajenifuja KO
Int J Cancer; 2022 Oct; 151(7):1142-1149. PubMed ID: 35666530
[TBL] [Abstract][Full Text] [Related]
32. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population.
Zhao XL; Hu SY; Zhang Q; Dong L; Feng RM; Han R; Zhao FH
J Gynecol Oncol; 2017 Jul; 28(4):e30. PubMed ID: 28541628
[TBL] [Abstract][Full Text] [Related]
33. A rapid HPV typing assay to support global cervical cancer screening and risk-based management: A cross-sectional study.
Inturrisi F; de Sanjosé S; Desai KT; Dagnall C; Egemen D; Befano B; Rodriguez AC; Jeronimo JA; Zuna RE; Hoffman A; Farhat Nozzari S; Walker JL; Perkins RB; Wentzensen N; Palefsky JM; Schiffman M
Int J Cancer; 2024 Jan; 154(2):241-250. PubMed ID: 37772799
[TBL] [Abstract][Full Text] [Related]
34. VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples.
Arbyn M; Peeters E; Benoy I; Vanden Broeck D; Bogers J; De Sutter P; Donders G; Tjalma W; Weyers S; Cuschieri K; Poljak M; Bonde J; Cocuzza C; Zhao FH; Van Keer S; Vorsters A
J Clin Virol; 2018 Oct; 107():52-56. PubMed ID: 30195193
[TBL] [Abstract][Full Text] [Related]
35. Urine collection in cervical cancer screening - analytical comparison of two HPV DNA assays.
Tranberg M; Jensen JS; Bech BH; Andersen B
BMC Infect Dis; 2020 Dec; 20(1):926. PubMed ID: 33276740
[TBL] [Abstract][Full Text] [Related]
36. Development and validation of real-time recombinase polymerase amplification-based assays for detecting HPV16 and HPV18 DNA.
Ying J; Mao L; Tang Y; Fassatoui M; Song W; Xu X; Tang X; Li J; Liu H; Jian F; Du Q; Wong G; Feng W; Berthet N
Microbiol Spectr; 2023 Dec; 11(6):e0120723. PubMed ID: 37787547
[TBL] [Abstract][Full Text] [Related]
37. Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study.
Agorastos T; Chatzistamatiou K; Tsertanidou A; Mouchtaropoulou E; Pasentsis K; Kitsou A; Moysiadis T; Moschaki V; Skenderi A; Katsiki E; Aggelidou S; Venizelos I; Ntoula M; Daponte A; Vanakara P; Garas A; Stefos T; Vrekoussis T; Lymberis V; Kontomanolis EN; Makrigiannakis A; Manidakis G; Deligeoroglou E; Panoskaltsis T; Decavalas GO; Michail G; Kalogiannidis I; Koukoulis G; Zempili P; Halatsi D; Truva T; Piha V; Agelena G; Chronopoulou A; Vaitsi V; Chatzaki E; Paschopoulos M; Adonakis G; Kaufmann AM; Hadzidimitriou A; Stamatopoulos K
Cancer Prev Res (Phila); 2019 Oct; 12(10):701-710. PubMed ID: 31427275
[TBL] [Abstract][Full Text] [Related]
38. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
Song F; Du H; Wang C; Huang X; Wu R;
PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
[TBL] [Abstract][Full Text] [Related]
39. Clinical Performance of the BD Onclarity Extended Genotyping Assay for the Management of Women Positive for Human Papillomavirus in Cervical Cancer Screening.
Volesky KD; Magnan S; Mayrand MH; Isidean SD; El-Zein M; Comète E; Franco EL; Coutlée F
Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):851-857. PubMed ID: 35131879
[TBL] [Abstract][Full Text] [Related]
40. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
